论文部分内容阅读
目的探讨长效干扰素联合恩替卡韦治疗慢性乙型病毒性肝炎临床效果,为临床治疗提供参考依据。方法选择2013年6月至2015年6月收治的72例慢性乙型病毒性肝炎(乙肝)患者作为研究对象,根据随机数字表法分为观察组与对照组,每组各36例,观察组给予长效干扰素联合恩替卡韦治疗,对照组给予恩替卡韦治疗。治疗3、6、12个月后比较两组患者的免疫功能、生化指标、乙肝e抗原(HBe Ag)转换率、乙型肝炎病毒(HBV)-DNA、HBV-DNA转阴率、HBV-DNA突破率等。结果治疗3、6、12个月,观察组谷氨酸-丙酮酸转氨酶(ALT)复常率、HBV-DNA水平、HBV-DNA转阴率、HBe Ag转换率均明显高于对照组(P<0.05,P<0.01);治疗12个月,观察组HBV-DNA突破率明显低于对照组(P<0.01);治疗12个月,观察组CD3+、CD4+、CD4+/CD8+明显高于对照组,CD8+明显低于对照组(P<0.05,P<0.01);两组患者不良反应发生率比较差异无统计学意义(P>0.05)。结论长效干扰素联合恩替卡韦可以更好地抑制HBV病毒的复制,改善了患者免疫功能,且未增加不良反应的发生,值得临床重视。
Objective To investigate the clinical efficacy of long-acting interferon combined with entecavir in the treatment of chronic hepatitis B virus and provide reference for clinical treatment. Methods Seventy-two patients with chronic hepatitis B (hepatitis B) who were admitted to our hospital from June 2013 to June 2015 were divided into observation group and control group according to the random number table method, 36 cases in each group, observation group Given long-acting interferon combined with entecavir treatment, the control group given entecavir treatment. After 3, 6 and 12 months of treatment, the immune function, biochemical indexes, HBeAg conversion rate, HBV DNA, HBV-DNA negative rate, HBV-DNA Breakthrough rate and so on. Results After treatment for 3, 6 and 12 months, the normalization rate of ALT, HBV-DNA, HBV-DNA negative rate and HBeAg conversion rate in the observation group were significantly higher than those in the control group (P (P <0.01). After 12 months of treatment, the breakthrough rate of HBV-DNA in observation group was significantly lower than that in control group (P <0.01). At 12 months of treatment, the levels of CD3 +, CD4 +, CD4 + / CD8 + in observation group were significantly higher than those in control group (P <0.05, P <0.01). There was no significant difference in the incidence of adverse reactions between the two groups (P> 0.05). Conclusion Long-acting interferon combined with entecavir can better inhibit HBV replication and improve immune function, and did not increase the incidence of adverse reactions, it deserves clinical attention.